Neuroblastoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (17 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Neuroblastoma}} | {{Neuroblastoma}} | ||
{{CMG}} | {{CMG}} {{AE}}{{ZAS}}{{HL}} | ||
==Overview== | ==Overview== | ||
[[Nuclear medicine]] studies used for [[diagnosis]] of neuroblastoma include fluorodeoxyglucose-18F [[positron emission tomography]] (18F- FDG PET) scan and [[metaiodobenzylguanidine]] (123I-MIBG) [[scintigraphy]]. 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other [[Differential diagnosis|differential diagnoses]]. 123I- MIBG scintigraphy distinguishes stage 3 and 4 neuroblastoma other [[Differential diagnosis|differential diagnoses]]. | |||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* Nuclear medicine | |||
** [[Nuclear medicine]] studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F [[positron emission tomography]] (18F-FDG PET) and [[metaiodobenzylguanidine]] (123I-MIBG) scintigraphy.<ref name="pmid19617326">{{cite journal| author=Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL| title=123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. | journal=J Nucl Med | year= 2009 | volume= 50 | issue= 8 | pages= 1237-43 | pmid=19617326 | doi=10.2967/jnumed.108.060467 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19617326 }} </ref><ref>{{Cite journal | |||
| author = [[Denah R. Taggart]], [[Myo M. Han]], [[Alekist Quach]], [[Susan Groshen]], [[Wei Ye]], [[Judith G. Villablanca]], [[Hollie A. Jackson]], [[Carina Mari Aparici]], [[David Carlson]], [[John Maris]], [[Randall Hawkins]] & [[Katherine K. Matthay]] | |||
| title = Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma | |||
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]] | |||
| volume = 27 | |||
| issue = 32 | |||
| pages = 5343–5349 | |||
| year = 2009 | |||
| month = November | |||
| doi = 10.1200/JCO.2008.20.5732 | |||
| pmid = 19805691 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[Nadja C. Colon]] & [[Dai H. Chung]] | |||
| title = Neuroblastoma | |||
| journal = [[Advances in pediatrics]] | |||
| volume = 58 | |||
| issue = 1 | |||
| pages = 297–311 | |||
| year = 2011 | |||
| month = | |||
| doi = 10.1016/j.yapd.2011.03.011 | |||
| pmid = 21736987 | |||
}}</ref> | |||
** 18F-FDG [[PET scan]] may distinguish stage 1 and 2 neuroblastoma from other [[differential diagnosis]]. | |||
** 123I-MIBG [[scintigraphy]] may distinguish stage 3 and 4 neuroblastoma from other [[differential diagnosis]]. | |||
** 123I-MIBG [[scintigraphy]] is superior than 18F-FDG PET scan in detecting [[bone marrow]] [[metastases]]. | |||
==References== | ==References== | ||
{{reflist|1}} | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 16:51, 4 March 2019
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma other imaging findings |
|
Risk calculators and risk factors for Neuroblastoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]
Overview
Nuclear medicine studies used for diagnosis of neuroblastoma include fluorodeoxyglucose-18F positron emission tomography (18F- FDG PET) scan and metaiodobenzylguanidine (123I-MIBG) scintigraphy. 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnoses. 123I- MIBG scintigraphy distinguishes stage 3 and 4 neuroblastoma other differential diagnoses.
Other Imaging Findings
- Nuclear medicine
- Nuclear medicine studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F positron emission tomography (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1][2][3]
- 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy may distinguish stage 3 and 4 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy is superior than 18F-FDG PET scan in detecting bone marrow metastases.
References
- ↑ Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). "123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma". J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.
- ↑ Denah R. Taggart, Myo M. Han, Alekist Quach, Susan Groshen, Wei Ye, Judith G. Villablanca, Hollie A. Jackson, Carina Mari Aparici, David Carlson, John Maris, Randall Hawkins & Katherine K. Matthay (2009). "Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (32): 5343–5349. doi:10.1200/JCO.2008.20.5732. PMID 19805691. Unknown parameter
|month=ignored (help) - ↑ Nadja C. Colon & Dai H. Chung (2011). "Neuroblastoma". Advances in pediatrics. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMID 21736987.